Product Details
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The NFAT (Luc) Jurkat Reporter Cell was engineered with the NFAT response element driving luciferase expressing systems. We could equip this reporter cell with a chimeric antigen receptor (CAR) for developing a CAR-J-based activity screening system. The anti-TCR/CD3 inducing intracellular signals could be inhibited by some transfected immune checkpoints binding to corresponding ligands.
Application
• Transfection host for some immune checkpoint concerning the NFAT signaling pathway
• The discovery of T cell activators by the NFAT signaling bioactivity
• Screen for anti-human CD3xTAA BsAb.

Growth Properties
Suspension
Selection Marker
Puromycin (5 μg/mL)
Complete Growth Medium
RPMI-1640 + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Receptor Assay

Expression analysis of human CD3 on NFAT (Luc) Jurkat Reporter Cell by FACS.
NFAT (Luc) Jurkat Reporter Cell were stained with APC-R700 labeled Anti-Human CD3 antibody or APC-R700 labeled Isotype antibody.Protocol
Application

Activating of NFAT signaling bioactivity by anti-human CD3 antibody (RLU).
This reporter cell was incubated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). The EC50 of anti-human CD3 antibody was approximately 0.078 μg/mL.Protocol
Activating of NFAT signaling bioactivity by anti-human CD3 antibody (FOLD).
This reporter cell was incubated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). The max induction fold was approximately 137.Protocol
Bioactivity detection of Anti-human CD3xCD19 bispecific antibody.
This reporter cell was incubated with serial dilutions of Blinatumomab (CD3×CD19 BsAb) in the presence of Raji cells that express human CD19 endogenously. The EC50 of Blinatumomab incubated with Raji cells is approximately 0.66 pM with the max induction fold 842.Protocol
Passage Stability

Passage stability analysis by anti-human CD3 antibody stimulation.
The continuously growing NFAT (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). Anti-human CD3 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 15-34.Protocol
Customer Reviews Writing Reviews

Important Statement
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.




















